Serum cystatin C is a determinant of central pressure augmentation index measured by oscillometric method in renal transplant recipients

BMC Nephrology

Christophe Mariat¹  Eric Alamartine¹  Ingrid Masson¹  Martin Jannot¹  Damien Thibaudin¹  Nicolas Maillard¹  Miriana Dinic¹ 

[1] Service de Néphrologie, Transplantation Rénale, Dialyse, Centre d'Hypertension Artérielle, Hôpital Nord, CHU de Saint-Etienne, Université Jean Monnet, PRES Université de Lyon, 42055 Saint Etienne, Cedex 04, France

关键词: Renal transplantation;    Cardiovascular risk;    Arterial stiffness;    Cystatin C;   

Others  :  1083482
DOI  :  10.1186/1471-2369-15-196

 received in 2014-03-27, accepted in 2014-11-18,  发布年份 2014

【 摘 要 】

Background

Serum cystatin C (ScysC) may help predicting cardiovascular outcome not only through its ability to detect renal dysfunction but also through its potential connection to others factors that are directly related to cardiovascular diseases. We explored the potential association of ScysC with arterial stiffness - a major contributor to cardiovascular disease - in renal transplant recipients (RTR).

Methods

Traditional and non-traditional cardio-vascular risk factors were collected from 215 stable RTR whom arterial stiffness was evaluated by the measure of the augmentation index of central pressure (AIx) determined by the arteriograph device. Serum creatinine and ScysC were measured the same day using standardized methods. Association between ScysC and AIx was examined in univariate and multivariate linear regression analysis.

Results

In univariate analysis, ScysC was strongly associated with AIx. This relationship was not confounded by age, gender, length of time spent on dialysis and transplantation vintage. Adjustment on the level of GFR estimated by the MDRD Study equation attenuated but did not abolish the association between ScysC and AIx.

Conclusions

In conclusion, ScysC is an independent predictor of AIx in RTR. Our data suggest that arterial stiffness may partially mediate the association between ScysC and cardiovascular risk in renal transplantation.

【 授权许可】

   
2014 Dinic et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ojo AO: Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006, 82(5):603-611.
• [2]Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A: Risk factors for late kidney allograft failure. Kidney Int 2002, 62(5):1848-1854.
• [3]Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol JASN 2000, 11(9):1735-1743.
• [4]Ducloux D, Kazory A, Chalopin J-M: Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004, 66(1):441-447.
• [5]Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367(1):20-29.
• [6]Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352(20):2049-2060.
• [7]Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006, 145(4):237-246.
• [8]Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey J, Gansevoort RT, CKD Prognosis Consortium: Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013, 369(10):932-943.
• [9]Masson I, Maillard N, Tack I, Thibaudin L, Dubourg L, Delanaye P, Cavalier E, Bonneau C, Kamar N, Morelon E, Moranne E, Alamartine E, Mariat C: GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis Off J Natl Kidney Found 2013, 61(2):279-284.
• [10]Masson I, Maillard N, Alamartine E, Mariat C: Serum Cystatin C in renal transplantation: beyond GFR estimation, a prognosis marker? Am J Transplant 2013. 13th ed. supplement 5
• [11]Séronie-Vivien S, Delanaye P, Piéroni L, Mariat C, Froissart M, Cristol JP, SFBC "Biology of renal function and renal failure" working group: Cystatin C: current position and future prospects. Clin Chem Lab Med CCLM FESCC 2008, 46(12):1664-1686.
• [12]Song SH, Kwak IS, Kim YJ, Lee HS, Rhee H, Lee DW, Kang YH, Kim SJ: Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hypertens Res Off J Jpn Soc Hypertens 2008, 31(10):1895-1902.
• [13]Madero M, Wassel CL, Peralta CA, Najjar SS, Sutton-Tyrrell K, Fried L, Canada R, Newman A, Shlipak MG, Sarnak MJ, Health ABC Study: Cystatin C associates with arterial stiffness in older adults. J Am Soc Nephrol JASN 2009, 20(5):1086-1093.
• [14]Odaira M, Tomiyama H, Matsumoto C, Yamada J, Yoshida M, Shiina K, Nagata M, Yamashina A: Association of serum cystatin C with pulse wave velocity, but not pressure wave reflection, in subjects with normal renal function or mild chronic kidney disease. Am J Hypertens 2010, 23(9):967-973.
• [15]Ozkok A, Akpinar TS, Tufan F, Kaya O, Bozbey HU, Atas R, Toz B, Atay K, Yilmaz E, Besiroglu M, Nas K, Hadrovic N, Illyés M, Ecder T: Cystatin C is better than albuminuria as a predictor of pulse wave velocity in hypertensive patients. Clin Exp Hypertens 2014, 36(4):222-6.
• [16]Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113(5):664-670.
• [17]Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, Pahor M, Bauer D, Newman A, Health ABC Study: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111(25):3384-3390.
• [18]Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999, 33(5):1111-1117.
• [19]Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37(5):1236-1241.
• [20]Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002, 106(16):2085-2090.
• [21]Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99(18):2434-2439.
• [22]London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001, 38(3):434-438.
• [23]Verbeke F, Maréchal C, Van Laecke S, Van Biesen W, Devuyst O, Van Bortel LM, Jadoul M, Vanholder R: Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011, 58(5):833-838.
• [24]Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997, 132(2):245-250.
• [25]London G, Covic A, Goldsmith D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Lindholm B, Martinez-Castelao A, Fliser D, Agarwal R, Jager KJ, Dekker FW, Blankestijn PJ, Zoccali C: Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl 2011, 1(1):10-12.
• [26]Delahousse M, Chaignon M, Mesnard L, Boutouyrie P, Safar ME, Lebret T, Pastural- Thaunat M, Tricot L, Kolko-Labadens A, Larras A, Haymann JP: Aortic stiffness of kidney transplant recipients correlates with donor age. J Am Soc Nephrol JASN 2008, 19(4):798-805.
• [27]Van Laecke S, Maréchal C, Verbeke F, Peeters P, Van Biesen W, Devuyst O, Jadoul M, Vanholder R: The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 2011, 26(7):2362-2369.
• [28]Courivaud C, Bamoulid J, Chalopin J-M, Gaiffe E, Tiberghien P, Saas P, Ducloux D: Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis 2013, 207(10):1569-1575.
• [29]Ducloux D, Challier B, Saas P, Tiberghien P, Chalopin J-M: CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol JASN 2003, 14(3):767-772.
• [30]Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, Boutouyrie P: Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006, 69(2):350-357.
• [31]Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt K-U, Nahas ME, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G: Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int 2007, 72(3):247-259.
• [32]Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T: Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011, 58(6):978-986.
• [33]Ferro CJ, Savage T, Pinder SJ, Tomson CRV: Central aortic pressure augmentation in stable renal transplant recipients. Kidney Int 2002, 62(1):166-171.